Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Adenovirus-specific CTLs for Adenovirus Related Disease in Immunocompromised Patients
NCT03425526Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2018
- Primary completion
- Jan 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic adenovirus-specific cytotoxic T lymphocytes in adenovirus infection, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events at 1 year and Assessment of response at 1 year. Started Mar 2018; status: recruiting.
02
Drugs
allogeneic adenovirus-specific cytotoxic T lymphocytes
03
Conditions
adenovirus infection
Beyond the preview
Go deeper on NCT03425526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03425526.